GLOBAL STUDIES

Paxman Map

We work alongside medical experts, professionals and world leaders in the field to provide extensive research, clinical studies and testing.

Independent observational studies have demonstrated the safety and effectiveness of the Paxman Scalp Cooling System in the prevention of chemotherapy induced hair loss with widely used chemotherapy dosages and regimens.

All trials have reported high levels of patient comfort and acceptability, with very low numbers of patients discontinuing scalp cooling. Our Clinical Efficacy Brochure details the proven performance in the most important and commonly referenced studies carried out using the Paxman Scalp Cooling System.

Komen et al., 2018

For FEC patients, a lengthened post-infusion time of 150 minutes improved the grade of alopecia, however, it did not improve the use of a wig/head covering.

Komen et al., 2016

For hair retention, a post infusion time of 20 minutes is as effective as 45-minute treatments for docetaxel 3-weekly schedules, leading to shorter hospital stays.

Vasconcelos, Wiesske & Schoenegg, 2018

German study shows scalp cooling giving an 88% success rate with paclitaxel and an overall success rate of 71% in patients treated with chemotherapy for breast cancer.

Nangia et al., 2017

Seven trial sites across the USA found scalp cooling to improve hair retention by 50%.

van den Hurk et al., 2013a

Scalp cooling has reduced the use of a wig or head cover by 40% when using the Paxman system.

van den Hurk et al., 2012b

50% of 1411 patients treated with a range of alopecia causing chemotherapy regimens, did not require a head covering while using scalp cooling.

Betticher et al., 2013

93.7% of patients reported to feel reasonably well or better when using the Paxman Scalp Cooler.

Martin et al., 2018

Scalp cooling reduces the prevalence of persistent alopecia in breast cancer patients.

In most cases, chemotherapy induced alopecia starts 2 weeks after the initial chemotherapy session and starts to reverse 3-4 months after the termination of the final treatment.

Rugo, Melin & Voigt, 2017

An American meta-analysis shows no difference in the incidence of scalp metastases between scalp cooled and non-scalp cooled patients.

Lemieux et al., 2014

Scalp cooling does not impact the survival of chemotherapy patients.

Kinoshita et al., 2019

Japanese multi-center controlled trial shows effective prevented alopecia with acceptable safety.  In addition scalp cooling resulted in faster recovery of hair volume after chemotherapy, even in patients for whom scalp cooling failed to prevent chemotherapy-induced alopecia.

J Bajpai et al., 2019

Results of Indian randomised controlled trial shows women with breast cancer receiving anthracycline or taxane chemotherapy with scalp cooling were significantly more likely to have less than 50% hair loss after a taxane chemotherapy, superior hair regrowth and improvement in patient reported outcomes, with acceptable tolerance.